简介:目的探讨社区获得性肺炎(CAP)患者呼出气冷凝液(EBC)和血清中8-异前列腺素(8-isoPG)对病情评估及疗效评价中的价值。方法选择CAP患者71例(CAP组),给予正规治疗,分别收集患者入院第1、3、7天EBC及血清标本,并记录患者入院时白细胞计数、红细胞沉降率、CURB-65评分。选择健康体检者46例(健康对照组),收集其EBC及血清标本。以酶免疫法测定EBC和血清中8-isoPG浓度。结果CAP患者EBC和血清中8-isoPG浓度均高于健康对照组,差异有统计学意义(P〈0.05)。与入院第1天比较,CAP患者入院第3、7天EBC和血清中8-isoPG浓度均下降,差异有统计学意义(P〈0.05)。CAP患者EBC和血清中8-isoPG浓度与CURB-65评分呈正相关(r分别为0.774、0.655,P〈0.05)。结论CAP患者体内存在不同程度的炎性反应和氧化应激,EBC和血清中的8-isoPG浓度对CAP的病情评估和疗效评价具有价值。
简介:摘要目的研究并分析口服普萘洛尔治疗婴儿血管瘤的护理措施。方法收集血管瘤患儿共72例,患儿均接受普萘洛尔口服治疗,分析治疗效果,并总结有效的护理措施。结果经过治疗,患儿的瘤体张力均出现了不同程度的减小,且颜色逐渐变淡,治疗优良率为80.56%(58/72)。72例患儿当中,只有10例患儿出现了心率略微减慢的不良反应,其余患儿无严重不良反应。结论在血管瘤患儿的治疗过程中,普萘洛尔口服能够获得良好的近期疗效,且不良反应发生率较低。在治疗过程中应加强观察护理,评估患儿是否存在药物禁忌证,保证治疗的顺利进行。
简介:Hypertensionisaleadingriskfactorforcardiovasculardisease,theleadingcauseofdeathandmorbidityinoursocietyandonaglobalscale.Majorcomponentsofcardiovasculardiseaseincludestroke,coronaryarterydisease,heartfailure,andchronickidneydisease,inallofwhichhypertensionplaysamajorrole.Theriskofthesecomplicationsincreasesdirectlyandlinearlywithsystolicbloodpressurestartingat115mmHg.Althoughusuallyasymptomatic,hypertensionisreadilydetectableonphysicalexaminationandisamenabletobothlifestylemodificationandpharmacologictreatmentinmostpatients.However,largeproportionsofthehypertensivepopulationremainundetectedandundertreated.Numerousguidelineshavebeenissuedduringthepastfewdecadestopromotedetectionandoptimaltherapy.Despitetheincreaseinriskwithsystolicbloodpressuregreaterthan115mmHg,thegenerallyacceptedthresholdfordiagnosisandtreatmenthasbeensystolicbloodpressuregreaterthan139mmHganddiastolicbloodpressuregreaterthan80mmHgbecauseuntilrecentlytreatmenttolowerlevelshasbeenassociatedwithanunfavorablerelationbetweenclinicalbenefitandharm.Inthepastseveralyears,newguidelines,advisories,commentaries,andclinicaltrialshaveprovidedevidenceforapotentialchangeincurrentrecommendationsforthemanagementofhypertension.Inthisregard,thelong-awaitedeighthreportoftheJointNationalCommitteeonthePrevention,Detection,Evaluation,andTreatmentofHighBloodPressurerecommendedpatientsolderthan60yearsbetreatedtoasystolicbloodpressureoflessthan150mmHg,whichhasgeneratedconsiderablecontroversyandcaution.ThestrikingfindingsoftheSystolicBloodPressureInterventionTrial(SPRINT)havereceivedconsiderableattentionbecauseofthedemonstrationthatintensivetherapytoatargetsystolicbloodpressurebelow120mmHgdecreasescardiovascularmortalityandmorbiditymorethanlessintensivetreatmenttoatargetsystolicbloodpressurebelow140mmHg
简介:目的分析普萘洛尔治疗肝硬化门静脉高压症的临床效果。方法选取漯河市郾城区中医院2013年1月—2014年1月收治的肝硬化门静脉高压症患者80例,按照随机数字表法分为观察组与对照组,每组40例。两组患者均给予基础治疗,观察组口服普萘洛尔,对照组口服5-单硝酸异山梨酯,观察两组患者门静脉血流量、脾静脉血流量及总胆红素(TBiL)、清蛋白(ALB)、丙氨酸氨基转移酶(ALT)水平。结果治疗前两组患者门静脉、脾静脉血流量比较,差异无统计学意义(P>0.05);治疗后两组患者门静脉、脾静脉血流量均低于治疗前,差异有统计学意义(P<0.05),且观察组门静脉、脾静脉血流量低于对照组,差异有统计学意义(P<0.05)。观察组TBiL、ALB、ALT低于对照组,差异有统计学意义(P<0.05)。结论普萘洛尔治疗肝硬化门静脉高压症效果显著,可有效降低患者门静脉、脾静脉血流量,进而降低门静脉、脾静脉压力及TBiL、ALB及ALT水平。